Avita Therapeutics/$RCEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Avita Therapeutics
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Ticker
$RCEL
Sector
Primary listing
Employees
260
Headquarters
Website
RCEL Metrics
BasicAdvanced
$206M
-
-$1.97
1.63
-
Price and volume
Market cap
$206M
Beta
1.63
52-week high
$14.16
52-week low
$3.60
Average daily volume
1M
Financial strength
Current ratio
0.579
Quick ratio
0.432
Long term debt to equity
-18.399
Total debt to equity
-345.858
Interest coverage (TTM)
-0.22%
Profitability
EBITDA (TTM)
-44.978
Gross margin (TTM)
84.28%
Net profit margin (TTM)
-68.87%
Operating margin (TTM)
-62.42%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-40.03%
Return on equity (TTM)
-935.73%
Valuation
Price to revenue (TTM)
2.368
Price to book
-13.96
Price to tangible book (TTM)
-9.89
Price to free cash flow (TTM)
-4.218
Free cash flow yield (TTM)
-23.71%
Free cash flow per share (TTM)
-1.603
Growth
Revenue change (TTM)
38.32%
Earnings per share change (TTM)
0.88%
3-year revenue growth (CAGR)
35.91%
3-year earnings per share growth (CAGR)
17.58%
What the Analysts think about RCEL
Analyst ratings (Buy, Hold, Sell) for Avita Therapeutics stock.
RCEL Financial Performance
Revenues and expenses
RCEL Earnings Performance
Company profitability
RCEL News
AllArticlesVideos
RCEL Investors Have Opportunity to Join AVITA Medical, Inc. Fraud Investigation with the Schall Law Firm
Business Wire5 days ago
RCEL Alert: Kirby McInerney LLP Encourages AVITA Medical, Inc. Investors to Inquire about Investigation
Business Wire1 week ago
Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Avita Therapeutics stock?
Avita Therapeutics (RCEL) has a market cap of $206M as of September 17, 2025.
What is the P/E ratio for Avita Therapeutics stock?
The price to earnings (P/E) ratio for Avita Therapeutics (RCEL) stock is 0 as of September 17, 2025.
Does Avita Therapeutics stock pay dividends?
No, Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Avita Therapeutics dividend payment date?
Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Avita Therapeutics?
Avita Therapeutics (RCEL) has a beta rating of 1.63. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.